BRAF and non-small cell lung carcinoma: Vemurafenib, Selumetinib, Binimetinib, PLX8394, RXDX‐105, LXH254+LTT462, AUY922 and Regorafenib are currently investigated in cinical trials in BRAF‐mutant NSCLC.